First-in-Human trial tests universal mRNA shot against deadly brain cancer
NCT ID NCT07306299
Summary
This early-stage trial is testing the safety of a new type of personalized mRNA vaccine designed to treat aggressive brain tumors that have returned or worsened after standard treatment. The study will enroll 10 patients to see if the vaccine is safe and if it can trigger the immune system to attack the cancer. Participants will receive a series of vaccine injections over many months while doctors closely monitor for side effects and any changes in their tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, HIGH GRADE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Room 521, Building 12, Jiefang Road Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.